Vail Successfully Completed (Oversubscribed) Initial Funding
At the end of August 2021, Vail Scientific successfully closed an oversubscribed round. The round was led by Vail Investor Group and its leader and Vail board member, Mike Nathan. Nathan shares, “I, along with the Vail Investor Group, have a real passion for transformative innovation. Sepsis diagnosis is a space that needs disruption. We are excited about the potential applications of this science.”
The round was followed by other engaged investors including the investor from our Series A Round. Our investors are committed to scientific advancement that improves the lives of others and understand the perpetual challenge that the proper detection of Sepsis poses to patients and the medical community at large.
Proceeds are being used to fund a proof-of-concept study to validate our initial pilot study. This is being run through our clinical partner, HealthPartners. Findings from this study will allow us to build a proprietary version of the diagnostic device.
CEO and co-founder Tom Burke says, “Vail Scientific is extremely excited to have a group of impassioned investors who look to bring about disruptive positive change to the challenge of Sepsis screening and treatment.”
As a team of inventors, we are ready to begin the next phase of our work.
Investor & Press Inquiries Contact:
info@vailscientific.com